Journal article · 2025 · Open access

729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis

Mengwen Huang, Fugang Li

Journal for ImmunoTherapy of Cancer, A835 · Published 1 November 2025 · DOI 10.1136/jitc-2025-sitc2025.0729

Open PDFView at the publisherCite this paper

In brief

“729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis” is a 2025 journal article by Mengwen Huang and Fugang Li, published in Journal for ImmunoTherapy of Cancer. OpenAlex counts 0 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Journal for ImmunoTherapy of Cancer.

Citations
0
Authors
2

Abstract

Background B cells are key players in several autoimmune diseases, contributing to disease pathogenesis through autoantibody production, T cell activation, and cytokine secretion. Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) are closely associated with B cell dysregulation. Recently, B cell-targeted therapies have emerged as promising treatments for these conditions. T cell engagers (TCEs) provide a more direct and robust mechanism for targeting B cells with reduced side effects, improved tissue penetration, making them a promising approach in the treatment of multiple autoimmune diseases.Methods EAE was induced in hCD3/hCD19/hCD20 mice to establish a robust disease model. Mice were then treated with either monoclonal antibodies targeting CD19/CD20 or TCEs designed to specifically target B cells. Clinical symptom scores, histopathological changes in the central nervous system, and immune cell subset dynamics were assessed to evaluate the efficacy and safety of the two therapeutic approaches. Additionally, serum cytokine levels and B cell surface marker expression were measured to elucidate the underlying mechanisms of action.Results TCE treatment demonstrated superior efficacy in reducing clinical symptoms and pathological demyelination in EAE mice compared to other therapies. TCEs effectively depleted B cells, inhibited autoantibody production, and restored immune cell balance. Moreover, TCE-treated mice exhibited fewer side effects and better overall safety profiles.Conclusions TCEs represent a promising novel B cell-targeted therapy for autoimmune diseases, showing enhanced efficacy and safety in mouse EAE model. This study provides valuable insights into the potential of TCEs as a new therapeutic strategy for B cell-mediated autoimmune diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Huang, M., & Li, F. (2025). 729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis. Journal for ImmunoTherapy of Cancer, A835. https://doi.org/10.1136/jitc-2025-sitc2025.0729

MLA 9

Huang, Mengwen, and Fugang Li. “729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis.” Journal for ImmunoTherapy of Cancer, 2025, p. A835. https://doi.org/10.1136/jitc-2025-sitc2025.0729.

Chicago

Huang, Mengwen and Fugang Li. 2025. “729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis.” Journal for ImmunoTherapy of Cancer: A835. https://doi.org/10.1136/jitc-2025-sitc2025.0729.

Harvard

Huang, M. and Li, F. (2025) ‘729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis’, Journal for ImmunoTherapy of Cancer, p. A835. doi:10.1136/jitc-2025-sitc2025.0729.

IEEE

M. Huang and F. Li, “729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis,” Journal for ImmunoTherapy of Cancer, p. A835, 2025, doi: 10.1136/jitc-2025-sitc2025.0729.

BibTeX

@article{huang2025exploring,
  title     = {{729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis}},
  author    = {Huang, Mengwen and Li, Fugang},
  journal   = {Journal for ImmunoTherapy of Cancer},
  year      = {2025},
  pages     = {A835},
  doi       = {10.1136/jitc-2025-sitc2025.0729},
  url       = {https://doi.org/10.1136/jitc-2025-sitc2025.0729}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies

  • T-cell engagers
  • multiple sclerosis
  • B-cell depletion
  • B cell-targeted therapy
  • experimental autoimmune encephalomyelitis
  • autoantibody production
  • demyelination
  • autoimmune disease biomarkers

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Huang, M., & Li, F. (2025). 729 Exploring the mechanism of action and related biomarkers of TCEs in multiple sclerosis. Journal for ImmunoTherapy of Cancer, A835. https://doi.org/10.1136/jitc-2025-sitc2025.0729

How many times has this paper been cited?

0 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal for ImmunoTherapy of Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Mengwen Huang, Fugang Li.

What is the DOI of this paper?

10.1136/jitc-2025-sitc2025.0729, permanently at https://doi.org/10.1136/jitc-2025-sitc2025.0729. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.